Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.C. Hastings.
Longman Group Ltd., (1985),
[2.]
M.J. Colston.
The microbiology of Mycobacterium leprae: progress in the last 30 years.
Trans R Soc Trop Med Hyg, 87 (1993), pp. 504-507
[3.]
World Health Organization.
WHO/LEP/95.1, (1995),
[4.]
S.M. van Beers, M. Hatta, P.R. Klatser.
Patient contact is the major determinant in incident leprosy: implications for future control.
Int J Lepr, 67 (1999), pp. 119-128
[5.]
D.S. Ridley, W.H. Jopling.
Classification of leprosy according to immunity: a five group system.
Int J Lepr, 34 (1966), pp. 255-273
[6.]
P. Feenstra.
Sustainability of leprosy control services in low-endemic situations.
Int J Lepr, 62 (1994), pp. 599-608
[7.]
Anónimo.
Consensus development statement on the chemotherapy of leprosy.
Int J Lepr, 60 (1992), pp. 644-649
[8.]
A. Sharma, V.K. Sharma, A. Rajwanshi, A. Das, I. Kaur, B. Kumar.
Presence of M. leprae in tissues in slit skin smear negative multibacillary (MB) patients after WHO-MBR.
Lepr Rev, 70 (1999), pp. 281-286
[9.]
K.W. Baumgart, W.J. Britton, R.J. Mullins, A. Basten, Rst.C. Barnetson.
Subclinical infection with Mycobacterium leprae - a problem for leprosy control strategies.
Trans R Soc Trop Med Hyg, 87 (1993), pp. 412-415
[10.]
J.M. Ponninhaus, L.J. Mwangasi, P.E.M. Fine, M.A. Shaw, A.C. Turner, S.M. Oxbourow, et al.
Is HIV infection a risk factor for leprosy?.
Int J Lepr, 59 (1991), pp. 221-228
[11.]
S.P. Zodpey, B.S. Bansod, S.N. Shrikhande, B.R. Maldhure, S.W. Kulkarni.
Protective effect of Bacillus Calmette Guérin (BCG) against leprosy: a population- based case-control study in Nagpur, India.
Lepr Rev, 70 (1999), pp. 287-294
[12.]
P.E.M. Fine.
Variation in protection by BCG: implications of and for heterologous immunity.
Lancet, 346 (1995), pp. 1.339-1.345
[13.]
S.K. Noordeen.
Elimination of leprosy as a public health problem.
Indian J Lepr, 63 (1991), pp. 401-409
[14.]
P.G. Smith.
Revised estimates of global leprosy numbers.
Lepr Rev, 62 (1992), pp. 317-318
[15.]
C.R. Revanker.
Dr Noorden meets with Pune dermatologists.
Lepr Rev, 70 (1999), pp. 398-399
[16.]
Organización Mundial de la Salud, 2000. Datos obtenidos de Internet: www.who.int/lep/lates%20statistics.htm; www.who.int/lep/13.htm y www. who.int/lep/det.htm
[17.]
World Health Organization. Leprosy elimination campaigns - reaching every patient in every village.
Wkly Epidemiol Rec, 72 (1997), pp. 205-212
[18.]
B.N. Mittal.
National strategy for elimination of leprosy in India.
Indian J Lepr, 64 (1992), pp. 513-520
[19.]
N.S. Dharmshaku.
Prospects of elimination of leprosy in India.
Indian J Lepr, 66 (1994), pp. 11-18
[20.]
M.F.R. Waters.
Chemotherapy of leprosy - current status and future prospects.
Trans R Soc Trop Med Hyg, 87 (1992), pp. 500-503
[21.]
S.K. Noordeen, L. López Bravo, T.K. Sundaresan.
Estimated number of leprosy cases in the world.
Lepr Rev, 63 (1992), pp. 282-287
[22.]
M. Becx-Bleumink.
Priorities for the future and prospects for leprosy control.
Int J Lepr, 66 (1993), pp. 82-101
[23.]
P. Feenstra.
Leprosy control through general health services and/or combined programmes.
Lepr Rev, 64 (1993), pp. 89-96
[24.]
P. Feenstra.
Will there be a need for leprosy control services in the 21st century?.
Lep Rev, 65 (1994), pp. 297-299
[25.]
The declaration of Alma-Ata 12 September 1978. International Conference on Primary Health Care jointly sponsored by WHO and UNICEF.
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
